Scientific Publications IXIARO® June 19, 2019 Cramer JP, Dubischar K, Eder S, Burchard GD, Jelinek T, Jilma B, Kollaritsch H, Reisinger E, Westritschnig K. Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study. May 1, 2019 Taucher, Kollaritsch, Dubischar Persistence of the immune response after vaccination with the Japanese encephalitis vaccine, IXIARO® in healthy adults: A five year follow-up study. September 1, 2018 Kadlecek, Borja-Tabora, Eder-Lingelbach, Gatchalian, Kiermayr, Sablan, Kundi, Taucher, Dubischar Antibody Persistence up to 3 Years After Primary Immunization With Inactivated Japanese Encephalitis Vaccine IXIARO in Philippine Children and Effect of a Booster Dose View More Lyme Disease September 1, 2017 Comstedt P, Schüler W, Meinke A, Lundberg U The novel Lyme borreliosis vaccine VLA15 shows broad protection against Borrelia species expressing six different OspA serotypes. November 4, 2015 Comstedt P, Hanner M, Schüler W, Meinke A, Schlegl R, Lundberg U. Characterization and optimization of a novel vaccine for protection against Lyme borreliosis. March 23, 2015 Schüler W, Bunikis I, Weber-Lehman J, Comstedt P, Kutschan-Bunikis S, Stanek G, Huber J, Meinke A, Bergström S, Lundberg U. Complete genome sequence of Borrelia afzelii K78 and comparative genome analysis. View More Chikungunya March 23, 2017 Roques P, Ljungberg K, Kümmerer BM, Gosse L, Dereuddre-Bosquet N, Tchitchek N, Hallengärd D, García-Arriaza J, Meinke A, Esteban M, Merits A, Le Grand R, Liljeström P. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus DUKORAL® May 1, 2018 Learoyd Asian travel: from the rare to the difficult. May 1, 2018 Learoyd, Gaut Cholera: under diagnosis and differentiation from other diarrhoeal diseases C. difficile May 17, 2016 Bézay N, Ayad A, Dubischar K, Firbas C, Hochreiter R, Kiermayr S, Kiss I, Pinl F, Jilma B, Westritschnig K. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers.